Xvivo Perfusion AB (publ)
XVIPY · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -12.56 | 1.48 | -1.79 | 0.22 |
| FCF Yield | -0.31% | -0.34% | 0.27% | 0.14% |
| EV / EBITDA | 543.33 | 251.55 | 517.34 | 758.59 |
| Quality | ||||
| ROIC | 0.32% | 1.23% | 0.51% | 0.94% |
| Gross Margin | 74.40% | 73.37% | 76.96% | 74.53% |
| Cash Conversion Ratio | 5.59 | 1.23 | 1.71 | 0.26 |
| Growth | ||||
| Revenue 3-Year CAGR | 16.27% | 22.66% | 25.58% | 26.63% |
| Free Cash Flow Growth | 18.38% | -183.94% | 74.21% | 353.98% |
| Safety | ||||
| Net Debt / EBITDA | -13.25 | -7.57 | -13.59 | -21.50 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.17 | 0.26 | 0.23 | 0.27 |
| Cash Conversion Cycle | 622.52 | 425.24 | 369.03 | 172.79 |